Asthma management with combination of fluticasone and formoterol: the Indian perspectiverspective
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20221046Keywords:
Asthma, Combination therapy, Fluticasone propionate, Formoterol fumarateAbstract
Asthma is a major health problem globally that affects people across all the age groups. The prevalence of asthma is increasing worldwide, especially in the low- and middle-income countries. Asthma is controlled with inhaled corticosteroid (ICS) with as-needed or daily low-dose therapy. A step-up therapy to daily combination treatment with low- or medium-dose ICS/long-acting β-agonist (LABA) may be required for those with persistent symptoms. Asthma control levels are low despite the availability of many therapies. The efficacy of inhaled asthma therapy is dependent on the efficiency and reliability with which the drug is delivered to the lungs. Combination of an ICS and a LABA in a single inhaler is a safe, effective, and convenient treatment option for asthma management. Fluticasone and formoterol in combination ensure high potency action against anti-inflammation and rapid bronchodilation, and is a well-established ICS-LABA dual therapy. Rapid bronchodilator action of formoterol and fluticasone’s long-term action against inflammation are vital clinical attributes for optimal asthma maintenance treatment. Fluticasone/formoterol combination therapy is an efficacious and safe alternative treatment option for patients with moderate to severe asthma. The combination of the two in a single inhaler is beneficial with regards to ease of administration and patient compliance.
Metrics
References
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:24.
Enilari O, Sinha S. The global impact of asthma in adult populations. Ann Glob Health. 2019;85(1):2.
Jain N, Satish K, Abhyankar N, Velayudhan N, Gurunathan J. Repeated exacerbation of asthma: An intrinsic phenotype of uncontrolled asthma. Lung India. 2019;36:131 8.
Sharma R, Iqbal ZA, Kalra H, Guliani A, Singh AK, Budhraja A, et al. An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients. Indian J Respir Care. 2021;10:196-200.
Salvi S, Kumar GA, Dhaliwal RS, Paulson K, Agrawal A, Koul PA, et al. India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: The Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6:e1363-74.
Salvi SS, Apte KK, Dhar R, Shetty P, Faruqi RA, Thompson PJ, et.al. Asthma insights and management in India: Lessons learnt from the Asia Pacific Asthma Insights and Management (AP AIM) Study. JAPI. 2015;63:36 43.
GINA. A pocket guide for healthcare professionals. Available at: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf. Accessed on 22 December 2021.
Nanda A, Wasan AN. Asthma in adults. Med Clin North Am. 2020;104(1):95-108.
Dhar R, Vora A. Stepping away from the blue inhaler in asthma management - A paradigm shift. JAPI. 2021;69:81-4.
Rajesh V, Augustine J, Divya R, Cleetus M. Inhaled formoterol-fluticasone single inhaler therapy in asthma: Real-world efficacy, budget impact, and potential to improve adherence. Can Respir J. 2020;8631316.
Papi A, Price D, Sastre J, Kaiser K, Lomax M, McIver T, et al. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. Respir Med. 2015;109:208 17.
Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma but has a more rapid onset of action: An open-label, randomised study. BMC Pulm Med. 2011;11(1):28.
Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, Callan C, et al. A randomised pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract. 2017;5(5):1378-87.
McKeage K. Fluticasone propionate/formoterol fumarate: A review of its use in persistent asthma. Drugs. 2013;73:195 206.
Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomised study. Adv Ther. 2012;29 (11):958-69.
Ming SWY, Haughney J, Small I, Wolfe S, Hamill J, Kevin Gruffydd-Jones K, et al. Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol: A real-life effectiveness and cost impact evaluation. Respir Med. 2017;129:199-206.
Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv. 2013;26(4):190-9.
Backer V, Ellery A, Borzova S, Lane S, Kleiberova M, Bengtsson P, et al. Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Ther Adv Respir Dis. 2018;12.
Price DB, Carter V, Martin J, Gardener EA, Skinner D, Yang S, et al. Comparative safety profile of the fixed-dose combination corticosteroid and long-acting β-2-agonist fluticasone propionate/formoterol fumarate: A 36-month longitudinal cohort study in UK primary care. Drugs. 2020;80(1):47-60.
Balki A, Balamurugan S, Bardapurkar S, Dalal S, Singh A, Singh BP, et al. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomised controlled trial. Pulm Pharmacol Ther. 2018;48:28-36.
Venkitakrishnan R, Thomas PK, Bansal A, Ghosh I, Dtcd Dnb JA, Divya R, et al. Fluticasone/formoterol compared with other ICS/LABAs in asthma: A systematic review. J Asthma. 2021;1-10.
Ghoshal A, Waghray P, Dsouza G, Saluja M, Agarwal M, Goyal A, et al. Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India. Pulm Pharmacol Ther. 2020;60:101869.
Downloads
Published
How to Cite
Issue
Section
